The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Open accessAbstract
BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind, controlled study. METHODS: We randomly assigned 161 patients who had active rheumatoid arthritis despite treatment with methotrexate to receive one of four treatments: oral methotrexate (> or =10 mg per week) (control); rituximab (1000 mg on days 1 and 15); rituximab plus cyclophosphamide (750 mg on days 3 and 17); or rituximab plus methotrexate. Responses defined according to the criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary analyses) and week 48 (exploratory analyses). RESULTS: At week 24, the proportion of patients with 50 percent improvement in disease symptoms according to the ACR criteria, the primary end point, was significantly greater with the rituximab-methotrexate combination (43 percent, P=0.005) and the rituximab-cyclophosphamide combination (41 percent, P=0.005) than with methotrexate alone (13 percent). In all groups treated with rituximab, a significantly higher proportion of patients had a 20 percent improvement in disease symptoms according to the ACR criteria (65 to 76 percent vs. 38 percent, P< or =0.025) or had EULAR responses (83 to 85 percent vs. 50 percent, P< or =0.004). All ACR responses were maintained at week 48 in the rituximab-methotrexate group. The majority of adverse events occurred with the first rituximab infusion: at 24 weeks, serious infections occurred in one patient (2.5 percent) in the control group and in four patients (3.3 percent) in the rituximab groups. Peripheral-blood immunoglobulin concentrations remained within normal ranges. CONCLUSIONS: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, a reversible depletion of normal B cells is a well-tolerated side effect of the anti-CD20 antibody rituximab, which is an efficacious therapy in mature B cell neoplasms and in autoimmune disease”
From The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer (2015) · cites this paper as Edwards et al., 2004
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Hof, M. A. V., Kuper, H. H., Leeuwen, M. A. V., van de Putte, L. B. A., & van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,250
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P. W., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,404
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,248
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B. J., Fürst, D. E., Goldsmith, C. H., Kieszak, S. M., Lightfoot, R. W., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,639
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
Takemura, S., Klimiuk, P. A., Braun, A. B., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4710 · Cited by 536
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J., & Cambridge, G. (2001) · Lara D. Veeken · doi:10.1093/rheumatology/40.2.205 · Cited by 525
Self-citationClinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 344
Self-citationvan Gestel, A. M., Anderson, J. J., van Riel, P. L. C. M., Boers, M., HAAGSMA, C. J., Rich, B., Wells, G. A., Lange, M., & Felson, D. T. (1999) · PubMed · Cited by 250
Do self‐perpetuating B lymphocytes drive human autoimmune disease?
Edwards, E., Cambridge, & Abrahams (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00772.x · Cited by 174
The role of B cells in rheumatoid arthritis
Dörner, T., & Burmester, G. R. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00011 · Cited by 164
Flagged first, then by citations
Research works printed but not linked: 3
- Van Gestel AM, 1999, J Rheumatol, 26, 705
- Tighe H, Carson DA. Rheumatoid factors. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 5th ed. Vol. 1. Philadelphia: W.B. Saunders, 1997:241-9.
- McLaughlin P, 1999, Semin Oncol, 26, 79
Cited by
Sorted by citations
Items 801–900 of 1,000
Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis
Wheater, G., Hogan, V. E., Teng, Y. K. O., Tekstra, J., Lafeber, F. P. J. G., Huizinga, T. W. J., Bijlsma, J. W. J., Francis, R. M., Tuck, S. P., Datta, H. K., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1607-0 · Cited by 50
Dye, J. R., Ullal, A. J., & Pisetsky, D. S. (2013) · Scandinavian Journal of Immunology · doi:10.1111/sji.12068 · Cited by 50
Schipper, L. G., Kievit, W., den Broeder, A. A., van der Laar, M. A., Adang, E., Fransen, J., & van Riel, P. L. C. M. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker084 · Cited by 50
Kasperkiewicz, M., Eming, R., Behzad, M., Hunzelmann, N., Meurer, M., Schulze‐Koops, H., von Wussow, P., Hertl, M., Zillikens, D., Freivogel, K., et al. (2012) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2012.07931.x · Cited by 50
van de Stadt, L. A., van Schouwenburg, P. A., Bryde, S., Kruithof, S., van Schaardenburg, D., Hamann, D., Wolbink, G., & Rispens, T. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/kes371 · Cited by 50
Management of Sight-Threatening Uveitis
Becker, M. D., Smith, J. R., Max, R., & Fiehn, C. (2005) · Drugs · doi:10.2165/00003495-200565040-00005 · Cited by 50
Chatzidionysiou, K., Lie, E., Nasonov, E. L., Lukina, G. V., Hetland, M. L., Tarp, U., Ancuta, I., Pavelká, K., Nordström, D., Gabay, C., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0951-z · Cited by 50
Martín-Mola, E., Balsa, A., García‐Vicuña, R., Gómez-Reino, J. J., González-Gay, M. Á., Sanmartí, R., & Loza, E. (2016) · Rheumatology International · doi:10.1007/s00296-016-3506-3 · Cited by 50
Bruijnen, S. T. G., Tsang-A-Sjoe, M. W. P., Raterman, H. G., Ramwadhdoebé, T. H., Vugts, D. J., van Dongen, G. A. M. S., Huisman, M. C., Hoekstra, O. S., Tak, P. P., Voskuyl, A. E., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1166-z · Cited by 50
da Mota, L. M. H., Kakehasi, A. M., Gomides, A. P. M., Duarte, Â. L. B. P., Cruz, B. A., Brenol, C. V., de Albuquerque, C. P., Pinheiro, G. D. R. C., Laurindo, I. M. M., Pereira, I. A., et al. (2018) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-018-0005-0 · Cited by 50
Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis
Nestorov, I. A., Munafo, A., Papasouliotis, O., & Visich, J. E. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008315312 · Cited by 50
Gerlag, D. M., & Tak, P. P. (2008) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2008.02.002 · Cited by 50
Corcione, A., Ferlito, F., Gattorno, M., Gregorio, A., Pistorio, A., Gastaldi, R., Gambini, C., Martini, A., Traggiai, E., & Pistoia, V. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2824 · Cited by 50
New therapies for systemic lupus erythematosus
Goldblatt, F., & Isenberg, D. A. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02795.x · Cited by 50
Modi, S. R., Soejima, M., & Levesque, M. C. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12114 · Cited by 49
To B or Not to B the Conductor of Rheumatoid Arthritis Orchestra
Moura, R. A., Graça, L., & Fonseca, J. E. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-012-8318-y · Cited by 49
Moazedi-Fuerst, F., Kielhauser, S., Brickmann, K., Hermann, J., Lutfi, A., Meilinger, M., Brezinschek, H., & Graninger, W. B. (2014) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2013.869617 · Cited by 49
Laragione, T., Brenner, M., Mello, A., Symons, M. H., & Gulko, P. S. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23610 · Cited by 49
Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis
Malur, A., Kavuru, M. S., Marshall, I., Barna, B. P., Huizar, I., Karnekar, R. R., & Thomassen, M. J. (2012) · Respiratory Research · doi:10.1186/1465-9921-13-46 · Cited by 49
Seidner, P. (2011) · Pain Physician · doi:10.36076/ppj.2011/14/e427 · Cited by 49
An update on dietary phenolic compounds in the prevention and management of rheumatoid arthritis
Rosillo, M. Á., Alarcón‐de‐la‐Lastra, C., & Sánchéz‐Hidalgo, M. (2016) · Food & Function · doi:10.1039/c6fo00485g · Cited by 51
In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor
Seijsing, J., Yu, S., Frejd, F. Y., Höidén‐Guthenberg, I., & Gräslund, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-23481-5 · Cited by 51
From autoinflammation to autoimmunity: old and recent findings
Caso, F., Costa, L., Nucera, V., Barilaro, G., Masala, I. F., Talotta, R., Caso, P., Scarpa, R., Sarzi‐Puttini, P., & Atzeni, F. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4209-9 · Cited by 53
Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis.
Alex, P., Szodoray, P., Knowlton, N. S., Dozmorov, I. M., Turner, M., Frank, M. B., Arthur, R. E., Willis, L. G., Flinn, D., HYND, R. F., et al. (2007) · PubMed · Cited by 48
Ding, C. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.11.1805 · Cited by 48
Fabris, M., Quartuccio, L., Lombardi, S., Saracco, M., Atzeni, F., Carletto, A., Cimmino, M. A., Fabro, C., Pontarini, E., Pellerito, R., et al. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.06.012 · Cited by 48
Strategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritis
Papagoras, C., Voulgari, P. V., & Drosos, A. A. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.04.002 · Cited by 48
Berlo, S. E., Guichelaar, T., ten Brink, C., van Kooten, P. J. S., Broere, F., Ludányi, K., van Eden, W., Broeren, C. P. M., & Glant, T. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22013 · Cited by 48
Rituximab alone as induction therapy for membranous lupus nephritis
Chavarot, N., Verhelst, D., Pardon, A., Caudwell, V., Mercadal, L., Sacchi, A., Leonardi, C. E., Guern, V. L., Karras, A., & Daugas, É. (2017) · Medicine · doi:10.1097/md.0000000000007429 · Cited by 48
The role of B cells and autoantibodies in rheumatoid arthritis
Chaiamnuay, S., & Bridges, S. L. (2005) · Pathophysiology · doi:10.1016/j.pathophys.2005.07.007 · Cited by 46
B-Cell Depletion and Repopulation in Autoimmune Diseases
Pers, J., Daridon, C., Bendaoud, B., Devauchelle‐Pensec, V., Berthou, C., Saraux, A., & Youinou, P. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8015-4 · Cited by 48
Chung, C. P., Thompson, J. L., Koch, G. G., Amara, I. A., Strand, V., & Pincus, T. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.048975 · Cited by 48
Reijm, S., Kwekkeboom, J. C., Blomberg, N. J., Suurmond, J., van der Woude, D., Toes, R. E. M., & Scherer, H. U. (2023) · JCI Insight · doi:10.1172/jci.insight.172006 · Cited by 48
Ferraccioli, G., Tolusso, B., Bobbio‐Pallavicini, F., Gremese, E., Ravagnani, V., Benucci, M., Podestà, E., Atzeni, F., Mannocci, A., Biasi, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040362 · Cited by 47
Rituximab in Systemic Lupus Erythematosus and Lupus Nephritis
Beckwith, H., & Lightstone, L. (2014) · Nephron Clinical Practice · doi:10.1159/000368585 · Cited by 47
Targeted biopharmaceuticals for cancer treatment
Zhou, L., Xu, N., Sun, Y. P., & Liu, M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.020 · Cited by 48
Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?
Benucci, M., Manfredi, M., Sarzi‐Puttini, P., & Atzeni, F. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.07.006 · Cited by 47
Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports
Lim, S.-S., Gillis, D., Smith, W., Hissaria, P., Greville, H. W., & Peh, C. A. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01055.x · Cited by 47
Kekow, J., Müller‐Ladner, & Schulze-Koops (2012) · Biologics · doi:10.2147/btt.s32244 · Cited by 47
Pellkofer, H., Voltz, R., & Kümpfel, T. (2009) · Muscle & Nerve · doi:10.1002/mus.21315 · Cited by 48
Role of Rituximab Therapy in Glomerulonephritis
Jayne, D. R. W. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070786 · Cited by 46
Schoergenhofer, C., Schwameis, M., Firbas, C., Bartko, J., Derhaschnig, U., Mader, R. M., Sunder‐Plaßmann, R., Jilma‐Stohlawetz, P., Desai, K., Misra, P., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-17934-6 · Cited by 48
Musters, A., Klarenbeek, P. L., Doorenspleet, M. E., Balzaretti, G., Esveldt, R. E., van Schaik, B. D. C., Jongejan, A., Tas, S. W., van Kampen, A. H. C., Baas, F., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800421 · Cited by 46
Immune-bone interplay in the structural damage in rheumatoid arthritis
Komatsu, N., & Takayanagi, H. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13188 · Cited by 47
Shim, S. C., Majstorović, L. B., Kasay, A. B., El-Khouri, E. C., Irazoque-Palazuelos, F. C., Cons-Molina, F., Medina-Rodriguez, F. G., Miranda, P., Shesternya, P. A., Chávez-Corrales, J., et al. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez152 · Cited by 47
Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
Serra‐Peinado, C., Grau-Expósito, J., Luque-Ballesteros, L., Astorga-Gamaza, A., Navarro, J., Gallego-Rodriguez, J., Martín-Castillo, M., Curran, A., Burgos, J., Ribera, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11556-4 · Cited by 47
Definition of B cell helper T cells in rheumatoid arthritis and their behavior during treatment
Lucas, C., Perdriger, A., & Amé-Thomas, P. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.06.021 · Cited by 48
Rituximab in non‐haematological disorders of adults and its mode of action
McDonald, V., & Leandro, M. J. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07718.x · Cited by 48
Mechanisms modulating inflammatory osteolysis: A review with insights into therapeutic targets
Shi, W., & Siegal, G. P. (2008) · Pathology - Research and Practice · doi:10.1016/j.prp.2008.07.002 · Cited by 47
Ioannou, Y., Lambrianides, A., Cambridge, G., Leandro, M. J., Edwards, J., & Isenberg, D. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.078402 · Cited by 47
Self-citationPathogenesis of rheumatoid arthritis
Kim, J. M., & Kim, H. (2010) · Journal of Korean Medical Association · doi:10.5124/jkma.2010.53.10.853 · Cited by 46
Vukelic, M., Li, Y., & Kyttaris, V. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02658 · Cited by 47
Duraisingham, S., Buckland, M. S., Grigoriadou, S., & Longhurst, H. J. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.902314 · Cited by 46
Thrombotic thrombocytopenic purpura: recognition and management
Kiss, J. E. (2010) · International Journal of Hematology · doi:10.1007/s12185-009-0478-z · Cited by 46
Guidelines for the drug treatment of rheumatoid arthritis.
da Mota, L. M. H., Cruz, B. A., Brenol, C., Pereira, I., Rezende-Fronza, L. S., Bértolo, M., Freitas, M. V., da Silva, N. D., Louzada-Júnior, P., Giorgi, R., et al. (2013) · Revista Brasileira de Reumatologia · doi:10.1016/s2255-5021(13)70020-8 · Cited by 50
Zidar, M., Kuzman, D., & Ravnik, M. (2018) · Soft Matter · doi:10.1039/c8sm00919h · Cited by 43
Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis
Orsolini, G., Fassio, A., Rossini, M., Adami, G., Giollo, A., Caimmi, C., Idolazzi, L., Viapiana, O., & Gatti, D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104354 · Cited by 46
Lessons for rituximab therapy in patients with rheumatoid arthritis
Garcia‐Montoya, L., Villota‐Eraso, C., Yusof, M. Y. M., Vital, E. M. J., & Emery, P. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30033-3 · Cited by 46
Self-citationZonozi, R., Wallace, Z. S., Laliberte, K. A., Huizenga, N. R., Rosenthal, J., Rhee, E. P., Cortazar, F. B., & Niles, J. L. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41501 · Cited by 46
Liu, S. M., Xavier, R. J., Good‐Jacobson, K. L., Chtanova, T., Newton, R. A., Sisavanh, M., Zimmer, S., Deng, C., Silva, D. G., Frost, M. J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.04.040 · Cited by 46
Hickman, R. A., Denniston, A. K., Yee, C., Toescu, V., Murray, P. I., & Gordon, C. (2009) · Lupus · doi:10.1177/0961203309347332 · Cited by 46
Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab
Kuek, A. Z. C., Hazleman, B. L., Gaston, H., & Östör, A. J. K. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel301 · Cited by 46
B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target
Dalakas, M. C. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.005 · Cited by 46
Multiple sclerosis treatment and infectious issues: update 2013
Winkelmann, A., Loebermann, M., Reisinger, E. C., & Zettl, U. K. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12226 · Cited by 45
Benham, H., Garske, L. A., Vecchio, P. C., & Eckert, B. (2010) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3181d0757f · Cited by 45
Biologic therapies: what and when?
Johnston, S. L. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.032300 · Cited by 46
B lymphocyte-typing for prediction of clinical response to rituximab
Brezinschek, H. P., Rainer, F., Brickmann, K., & Graninger, W. B. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3901 · Cited by 45
Biomarkers to guide clinical therapeutics in rheumatology?
Robinson, W. H., & Mao, R. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000250 · Cited by 47
Ahmed, A., & Foster, C. S. (2018) · Ophthalmic Research · doi:10.1159/000486791 · Cited by 45
Winthrop, K. L., Saag, K. G., Cascino, M. D., Pei, J., John, A. K., Jahreis, A., Haselkorn, T., & Furst, D. E. (2018) · Arthritis Care & Research · doi:10.1002/acr.23781 · Cited by 45
The Use of Biological Agents in the Treatment of Rheumatoid Arthritis
Fan, P.-T., & Leong, K. (2007) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v36n2p128 · Cited by 45
Successful treatment of rheumatoid meningitis with cyclophosphamide but not infliximab
Chou, R. C., Henson, J. W., Tian, D., Hedley‐Whyte, E. T., & Reginato, A. M. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.042093 · Cited by 45
Eisenberg, R. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.042648 · Cited by 45
Anti‐CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis
Korhonen, R., & Moilanen, E. (2009) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2009.00452.x · Cited by 45
Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance
Pinney, J. J., Rivera‐Escalera, F., Chu, C. C., Whitehead, H. E., VanDerMeid, K. R., Nelson, A. M., Barbeau, M. C., Zent, C. S., & Elliott, M. R. (2020) · Blood · doi:10.1182/blood.2020005571 · Cited by 44
He, C., Li, W., Xie, Q., & Yin, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.820163 · Cited by 44
Navas, N., Herrera, A., Martínez-Ortega, A., Salmerón‐García, A., Barrera, J. C., & Cuadros-Rodrı́guez, L. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-7368-1 · Cited by 44
Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280586 and Rituximab (MabThera®)
Ryan, A. M., Sokolowski, S. A., Ng, C.-K., Shirai, N., Collinge, M., Shen, A. C., Arrington, J., Radi, Z. A., Cummings, T., Ploch, S. A., et al. (2014) · Toxicologic Pathology · doi:10.1177/0192623313520351 · Cited by 44
B cells as under-appreciated mediators of non-auto-immune inflammatory disease
Nikolajczyk, B. S. (2010) · Cytokine · doi:10.1016/j.cyto.2010.02.022 · Cited by 42
B Cell Depletion Inhibits Spontaneous Autoimmune Thyroiditis in NOD.H-2h4 Mice
Yu, S., Dunn, R., Kehry, M. R., & Braley‐Mullen, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7706 · Cited by 44
Anti-CD79 Antibody Induces B Cell Anergy That Protects against Autoimmunity
Hardy, I. R., Anceriz, N., Rousseau, F., Seefeldt, M. B., Hatterer, E., Irla, M., Buatois, V., Chatel, L., Getahun, A., Fletcher, A., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302672 · Cited by 43
Biologic efficacy optimization—a step towards personalized medicine
Kiely, P. D. W. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/kev356 · Cited by 44
Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy
Gazzola, S., Delmont, É., Franques, J., Boucraut, J., Salort‐Campana, E., Verschueren, A., Sagui, E., Hubert, A.-M., Pouget, J., & Attarian, S. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.04.015 · Cited by 44
Henry, J., Gottenberg, J., Rouanet, S., Pavy, S., Sellam, J., Tubach, F., Belkhir, R., Xavier Mariette, A., Séror, R., & for the Auto-Immunity and Rituximab investigators (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex446 · Cited by 44
Litchman, T., Roy, B., Kumar, A., Sharma, A., Njike, V. Y., & Nowak, R. J. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116690 · Cited by 44
Misra, R., Sharma, B., Gupta, R., Pandya, S., Agarwal, S., Agarwal, P., Grover, S., Sarma, P., & Wangjam, K. (2008) · Indian Journal of Rheumatology · doi:10.1016/s0973-3698(10)60373-1 · Cited by 46
B Cell-Targeted Therapy for Rheumatoid Arthritis
Looney, R. J. (2006) · Drugs · doi:10.2165/00003495-200666050-00004 · Cited by 44
Recillas-Gispert, C., Serna‐Ojeda, J. C., & Flores-Suárez, L. F. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-3198-5 · Cited by 43
Störch, H., Zimmermann, B., Resch, B., Tykocinski, L., Moradi, B., Horn, P., Kaya, Z., Blank, N., Rehart, S., Thomsen, M. N., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206965 · Cited by 44
Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus
Vezzoli, P., Berti, E., & Marzano, A. V. (2008) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.4.3.351 · Cited by 43
Couderc, M., Mathieu, S., Pereira, B., Glace, B., & Soubrier, M. (2012) · Arthritis Care & Research · doi:10.1002/acr.21865 · Cited by 43
Lavielle, M., Mulleman, D., Goupille, P., Bahuaud, C., Sung, H. C., Watier, H., & Thibault, G. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1152-5 · Cited by 43
B Lymphocyte Depletion in Rheumatoid Arthritis:Targeting of CD20
Edwards, J., Leandro, M. J., & Cambridge, G. (2004) · KARGER eBooks · doi:10.1159/000082103 · Cited by 43
Self-citationPi, X., Tan, S., Hayes, M., Liqun, X., Shayman, J. A., Ling, S., & Holoshitz, J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21635 · Cited by 43
Polysaccharide-specific B cell responses to vaccination in humans
Mitchell, R. M., Kelly, D. F., Pollard, A. J., & Trück, J. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28350 · Cited by 43
Furukawa, S., Yasuda, S., Amengual, O., Horita, T., Atsumi, T., & Koike, T. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.046870 · Cited by 43
Successful Use of Rituximab for Cutaneous Vasculitis
Chung, L. S. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.11.1407 · Cited by 43
Celiac disease 2015 update: new therapies
Veeraraghavan, G., Leffler, D. A., Kaswala, D. H., & Mukherjee, R. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1033399 · Cited by 43
Precision medicine in rheumatoid arthritis
Bhamidipati, K., & Wei, K. S. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101742 · Cited by 43
Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab.
Markatseli, T. E., Kaltsonoudis, E., Voulgari, P. V., Zioga, A., & Drosos, A. A. (2009) · PubMed · Cited by 42
Metadata
- Authors
- Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T.
- Affiliations
- University College London (GB)
- University of Wrocław (PL)
- Roche (United Kingdom) (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-17
- Volume
- 350
- Issue
- 25
- Pages
- 2572-2581
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118994799
- Cited by
- 2,623
- References
- 21
- Citations by year
- 2026: 65 · 2025: 69 · 2024: 76 · 2023: 62 · 2022: 61 · 2021: 85 · 2020: 87 · 2019: 85 · 2018: 103 · 2017: 112 · 2016: 96 · 2015: 103 · 2014: 129 · 2013: 133 · 2012: 133
- FWCI
- 109.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- rheumatoid arthritis, rituximab, B-cell depletion, cyclophosphamide, methotrexate, combination therapy, adverse events, serious infections, immunoglobulin levels, treatment-resistant rheumatoid arthritis, ACR response criteria, EULAR response criteria, maintenance therapy, relapse prevention, long-term follow-up, drug efficacy
- MeSH terms
- Rituximab, Antibodies, Monoclonal, Arthritis, Rheumatoid, B-Lymphocytes, Bacterial Infections, Cyclophosphamide, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Methotrexate, Middle Aged, Antirheumatic Agents, Antigens, CD20, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
